SRX Global Inc. has entered into a secured financing transaction with CERo Therapeutics Holdings, Inc. (CERO), providing up to $11.7 million in total funding. The agreement consolidates existing debt and offers new capital to CERO for working capital and to pay outstanding trade payables.
Key Details
- Agreement: On August 27, 2026, CERO issued a Consolidated Senior Secured Promissory Note to SRX Global.
- Financial Terms: The note consolidates $5,666,108.77 in prior notes and provides for up to $6,000,000 in additional advances, for a maximum loan amount of $11,666,108.77. The note bears interest at 10% per annum and matures on October 15, 2026, with potential extensions.
- Security: The financing is secured by a first-priority interest in the capital stock of CERO's wholly-owned subsidiary, CERo Therapeutics, Inc., and substantially all of the subsidiary’s assets, including intellectual property related to its CER-T cell therapy business.